Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDH1 | P40925 | 1/20 | 0.34 |
| ▸ | MDH2 | P40926 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18308571 | 1.00 | MDH1 (0.34) | MDH1MDH2HSD11B1DPP8DPP9 | |
| SCHEMBL12304939 | 1.00 | MDH1 (0.34) | MDH1MDH2HSD11B1DPP8DPP9 | |
| SCHEMBL11985998 | 0.97 | MDH1 (0.35) | MDH1MDH2HSD11B1DPP8DPP9 | |
| SCHEMBL132070 | 0.90 | — | — | |
| SCHEMBL16865927 | 0.90 | — | — | |
| SCHEMBL14253578 | 0.90 | CYP17A1 (0.33) | MDH1MDH2CYP17A1CYP19A1 | |
| SCHEMBL13847331 | 0.89 | MDH1 (0.40) | MDH1MDH2HSD11B1DPP8DPP9 | |
| SCHEMBL11966898 | 0.88 | HSD11B1 (0.38) | MDH1MDH2HSD11B1DPP8DPP9 | |
| SCHEMBL18308561 | 0.87 | CYP19A1 (0.40) | CYP17A1CYP19A1ALDH1A1 | |
| SCHEMBL132052 | 0.87 | CYP19A1 (0.40) | CYP17A1CYP19A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015297-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, NOVEL COMPOUND, AND ACID GENERATOR | TOKYO OHKA KOGYO.CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120015299-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, NOVEL COMPOUND, AND ACID GENERATOR | TOKYO OHKA KOGYO CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20100330499-A1 | METHODS OF FORMING ELECTRONIC DEVICES | ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015299-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, NOVEL COMPOUND, AND ACID GENERATOR | RER1, ASIC1, ABCC1 | MDH1 2317/4885MDH2 1011/4885HSD11B1 888/4885 |
| US-20120015297-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, NOVEL COMPOUND, AND ACID GENERATOR | ASIC1, SLC11A2, RER1 | MDH1 1983/4885MDH2 807/4885HSD11B1 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.